Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | USP28 |
| Gene Name: | USP28 |
| Protein Full Name: | Ubiquitin carboxyl-terminal hydrolase 28 |
| Alias: | Ubiquitin thioesterase 28 |
| Mass (Da): | 122491 |
| Number AA: | 1077 |
| UniProt ID: | Q96RU2 |
| Locus ID: | 57646 |
| COSMIC ID: | USP28 |
| Gene location on chromosome: | 11q23.2 |
| Cancer protein type: | OP/TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 20285 |
| Percent of cancer specimens with mutations: | 1.06 |
| Normal role description: | Disrupts ubiquitin protein and inactivates ubiquitin pathways. USP28 is involved in DNA damage response checkpoint and MYC proto-oncogene stability. USP28 facilitates DNA damage induced apoptosis by specifically deubiquitinating proteins of the DNA damage pathway such as CLSPN. USP28 also deubiquitinates MYC in the nucleoplasm preventing MYC degradation by the proteasome. These two physiologic functions appear to have competing effects on oncogenesis - one inhibiting (facilitating apoptosis) and one promoting (prevents MYC degredation). |